Organic compounds -- part of the class 532-570 series – Organic compounds – Radioactive metal containing
Patent
1997-12-18
1999-11-16
Gonzalez, Porfirio Nazario
Organic compounds -- part of the class 532-570 series
Organic compounds
Radioactive metal containing
252 1, 424 11, 544225, 544226, 546 2, 546 6, 556 1, 556 42, 556 45, 556 57, 556 81, 556113, 556130, 556137, 562561, C07F 1300, C07F 1500, C07F 300
Patent
active
059860740
ABSTRACT:
The present invention relates to novel metal chelates, exemplified as technetium-99m or rhenium chelates, and to the process of preparing such metal chelates from corresponding ligands. These ligands and their corresponding metal chelates are synthesized to have a cysteinylethylene (EC) structure, a monothiourea (MTU) structure, or a dithiourea (DTU) structure. The present invention further relates to a pharmaceutical composition comprising a metal chelate, for example, a .sup.99m Tc-chelate, to the use of the composition for renal imaging and examination of renal function, and to a kit for preparing such a composition prior to use.
REFERENCES:
patent: 4849511 (1989-07-01), Verbruggen
patent: 4925650 (1990-05-01), Nosco et al.
patent: 5011676 (1991-04-01), Thakur
patent: 5037631 (1991-08-01), Nosco
patent: 5104638 (1992-04-01), Nosco
patent: 5116598 (1992-05-01), Nosco
patent: 5187264 (1993-02-01), Verbruggen
patent: 5245018 (1993-09-01), Kondo et al.
patent: 5268163 (1993-12-01), Verbruggen
patent: 5308603 (1994-05-01), Thakur
patent: 5419905 (1995-05-01), Nosco
Alazraki, N.P. et al., "Stress Thallium SPECT is Equally Effective for Predicting Outcomes for Women and Men in the Emory Angioplasty Versus Surgery Trial (East)," (1986) Soc. Of Nuclear Medicine 43.sup.rd Annual Meeting Abstract 53068.
Blaufox, M.D., "Procedures of Choice in Renal Nuclear Medicine," (1991) J. Nuclear Medicine 32(6):1301-1309.
Bubeck, B. et al., "Pharmacokinetics of Technetium-99m-MAG.sub.3 in Humans," J. Nuclear Medicine (Aug. 1990) 31(8):1285-1293.
Dogan, A.S. and Kirchner, P.T., "Hepatobiliary Excretion of MAG3 Simulation of a Urinary Leak," (1993) Clinical Nuclear Medicine 18(9):746-750.
Eshima, D. et al., "Biological Studies on a New Class of Tc-99m Renal Tubular Function Agents," (1986) Current Applications in Radiopharmacology 237-247.
Eshima, D. et al., "Animal Evaluation of Technetium-99m Triamide Mercaptide Complexes as Potential Renal Imaging Agents," J. Nuclear Medicine (Jul. 1987) 28(7):1180-1186.
Eshima, D. and Taylor, A. Jr., "Technetium-99m (.sup.99m Tc) Mercaptoacetyltriglycine: Update on the New .sup.99m Tc Renal Tubular Function Agent," (1992) Seminars in Nuclear Medicine XXII(2):61-73.
Eshima, D. et al., "Evaluating the Role of Protein Binding on the Renal Extraction of Tc-99m Tubular Agents Utilizing an Isolated Perfused Rat Kidney Model," (1996) Society of Nuclear Medicine 43.sup.rd Annual Meeting Abstract 37990.
Eshima, D. et al., "Preparation and Evaluation of Tc-99m Sulfur Colloid for Lymphoscinitigraphy Studies," (1996) Society of Nuclear Medicine 43.sup.rd Annual Meeting Abstract 37987.
Halkar, R.K. et al., "Interoperator Variability in Quantitating the MAG3 Renal Uptake Based on Semiautomated and Manual Regions of Interest," (1996) Society of Nuclear Medicine 43.sup.rd Annual Meeting Abstract 53086.
Halkar, R.K. et al., "Coronary Collaterals and Reversibility in Stress/Rest Reinjection TL-201 Myocardial Images," (1996) Society of Nuclear Medicine 43.sup.rd Annual Meeting Abstract 53085.
Hansen, L. et al., "A Promising Renal Tubular Function Agent that Combiines the Structural Features of MAG.sub.3 and EC," Proceedings of 43.sup.rd Annual Meeting, J. Nuclear Medicine (May 1996 Supplement) 37(5):17P.
Jafri, R.A. et al., "Technetium-99m MAG.sub.3, A Comparison with Iodine-123 and Iodine-131 Orthoiodohippurate, in Patients with Renal Disorders," (1988) J. Nuclear Medicine 29(2):147-158.
Jones, M.E. et al., "Solid Phase Gastric Emptying T1/2 Measurements Using Two Data Points," (1996) Society of Nuclear Medicine 43.sup.rd Annual Meeting Abstract 39024.
Lipowska, M. et al., "Synthesis and Characterization of Rhenium(V) Oxo Complexes with a New Thio-Amide-Thiourea Ligand System. X-ray Crystal Structure of [1-Phenyl-3-[2-((2-thioacetyl)amino)ethyl]thioureato]oxorhenium(V)" Inorg. Chem. (1996) 35:4484-4489.
Lipowska, M. et al., "Rhenium(v) Oxo Complexes of Novel N.sub.2 S.sub.2 Dithiourea (DTU) Chelate Ligands: Synthesis and Structural Characterization," Inorganic Chemistry (1996) 35(14):4228-4231.
Lipowska, M. et al., "A New Versatile Method for Creating Small N.sub.2 S.sub.2 Ligands Linked to Targeting Components," Proceedings of 43.sup.rd Annual Meeting, J. Nuclear Medicine (1996) 37(5):190P.
Lipowska, M. et al., "A New One-Step Ligand Synthesis for Preparing Easily Targeted Small Neutral Tc-99m N.sub.2 S.sub.2 Complexes," Proceedings of 43.sup.rd Annual Meeting, J. Nuclear Medicine (1996) 37(5):191P.
Marzilli, L.G. et al., "Linking Deprotonation and Denticity of Chelate Ligands. Rhenium (V) Oxo Analogues of Technetium-99m Radiopharmaceuticals Containing N.sub.2 S.sub.2 Chelate Ligands," (1994) Inorganic Chemistry 33:4850-4860.
Russell, C.D. et al., "Comparison of Technetium-99m MAG.sub.3 with Iodine-131 Hippuran by a Simultaneous Dual Channel Technique," (1988) J. Nucl. Med. 29:1189-1193.
Schaap, G.H. et al., ".sup.99m Tc-MAG3: Dynamic studies in patients with renal disease," (1988) Eur. J. Nucl. Med. 14:28-31.
Shattuck, L.A. et al., "Evaluation of the Hepatobiliary Excretion of Technetium-99m-MAG3 and Reconstitution Factors Affecting Radiochemical Purity," J. Nuclear Medicine (Feb. 1994) 35(2):349-355.
Taylor, A. et al., "Comparison of Tc-99mO(N,N'-Ethylenedicysteine Isomers in Rats and in Normal Volunteers," (1996) Society of Nuclear Medicine 43.sup.rd Annual Meeting Abstract 53089.
Taylor, A., Jr. et al., "Technetium-99m MAG.sub.3 Kit Formulation: Preliminary Results in Normal Volunteers and Patients with Renal Failure," J. Nuclear Medicine (May 1988) 29(5):616-622.
Taylor, A. Jr. et al., "Comparison of Iodine-131 OIH and Technetium-99m MAG.sub.3 Renal Imaging in Volunteers," (1986) J. Nuclear Medicine 27(6):795-803.
Taylor, A. Jr. et al., "Clinical Comparison of I-131 Orthoiodohippurate and the Kit Formulation of Tc-99m Mercaptoacetyltriglycine," (1989) Radiology 170(3):721-725.
Taylor, A. Jr. and Eshima, D., "Effects of Altered Physiologic States on Clearance and Biodistribution of Technetium-99m MAG.sub.3, Iodine-131 OIH, and Iodine-125 Iothalamate," (1988) J. Nuclear Medicine 29(5):669-675.
Taylor, A. Jr. et al., "Evaluation of Tc-99m Mercaptoacetyltriglycine in Patients with Impaired Renal Function," (1987) Radiology 162:365-370.
Taylor, A. Jr. et al., ".sup.99m Tc-MAG.sub.3, a new renal imaging agent: Preliminary results in patients," (1987) Eur. J. Nucl. Med. 12:510-514.
VanNerom, C. et al., "Comparison of Renal Excretion Characteristics of Isomers L,L and D,D of Tc-99m Ethylenedicysteine," J. Nuclear Medicine, Proceedings of the 37.sup.th Annual Meeting, p. 806.
Verbruggen, A.M. et al., "Technetium-99m-L,L-Ethylenedicysteine: A Renal Imaging Agent. I. Labeling and Evaluation in Animals," J. Nuclear Medicine (Apr. 1992) 33(4):551-557.
Verbruggen, A. et al., "Evaluation of the Diastereomers of Tc-99m-Mercaptoace-Tylglycyl-D-Alanylglycine (Tc-99m-D-MAGAG) in Primates," Proceedings of the 35.sup.th Annual Meeting, J. Nuclear Medicine (May 1988) 29(5);909-910.
Hansen Lory
Lipowska Malgorzata
Marzilli Luigi G.
Taylor, Jr. Andrew
Emory University
Gonzalez Porfirio Nazario
LandOfFree
Metal chelates as pharmaceutical imaging agents, processes of ma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metal chelates as pharmaceutical imaging agents, processes of ma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metal chelates as pharmaceutical imaging agents, processes of ma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1326348